Prevention of prostate cancer by androgens: Experimental paradox or clinical reality

European Urology

Volumn 46, Issue 3, 2004, Pages 285-295

  Algarté Génin, Michèle ^a   Cussenot, Olivier ^a,b   Costa, Pierre ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL TENON   (France)

^c Hopital Gaston Doumergue   (France)

Author keywords

5 reductase inhibitors; Androgen antagonists; Androgen receptor; Androgens; Hormonal replacement therapy; Prevention; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; FIBROBLAST GROWTH FACTOR 10; FINASTERIDE; KERATINOCYTE GROWTH FACTOR; PRASTERONE; PROTEIN P21; RETINOIC ACID DERIVATIVE; RETINOID; TESTOSTERONE; VITAMIN D;

ANDROGEN BLOOD LEVEL; APOPTOSIS; BINDING AFFINITY; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION RESPONSE; EPITHELIUM CELL; EVOLUTION; GENE EXPRESSION; HORMONE ACTION; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; IMMUNE SYSTEM; NONHUMAN; PALPATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; RISK BENEFIT ANALYSIS; STEROID BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL;

EID: 4043160542     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.04.012     Document Type: Review

References (6)

1. Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L,Slingerland J. Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene 2000;19:670–679
2. Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994;54:1566–1573.
3. Zhao X.Y., Ly L.H., Peehl D.M., Feldman D. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999;140(3),pp:1205–12
4. Sadar MD, Gleave ME. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res 2000;60:5825–31.
5. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H.Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma by activation of the androgen receptor. Cancer Research 1998;58:4640–4645
6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R.Molecular determinants of resistance to antiandrogen therapy.Nature Medicine 2004;10 pp:33–39.